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Over the past two decades important progress has been
made in the area of intervention in psychiatric disorders,
mainly with the introduction of novel antidepressant
and antipsychotic drugs. Despite these advances, the
interindividual differences in the psychotropic drug
response and the development of drug-induced adverse
effects remain a serious problem in clinical practice. On
the other hand, more information about the mechan-
isms of action of psychotropic drugs may help the way
they should be prescribed. In this regard application of
technological advances in the field of neurosciences,
namely modern neuroimaging methods and the enor-
mously developed molecular genetics acquires para-
mount importance. PET and SPECT studies have
indicated that antipsychotic response is associated with
blockade of dopamine D2 receptors and antidepressant
response has been linked to blockade of serotonin trans-
porter receptors. According to Zipurski et al (2007),
these findings have the following clinical implications: a)
antipsychotic dosing for most patients with schizophre-
nia can be expected to occur within a narrow range of
D2 receptor blockade, (b) Antidepressant response for
must patients can be expected to occur with blockade of
80% or more of the serotonin transporter. Pharmacoge-
netics and pharmacogenomics signal the beginning of a
new era in the treatment psychiatric disorders. They
provide a novel method in the search of informative
correlates of psychotropic drug response. Polymorph-
isms of dopamine and serotonin receptor subtypes,
transporter proteins and metabolic enzymes may contri-
bute to variability in response to psychotropic drugs and
the occurrence of their adverse reactions. In the field of
molecular biology, it has been demonstrated that psy-
chotropic drugs used to treat mood disorders, target
molecules and signaling cascades implicated in the
control of neuroplasticity. Our expanding knowledge of
psychopharmacology will help lead to specific targeting
for more predictable and safer medications in the near
future. It is believed that perspectives are outstanding to
achieve benefits previously unattainable.
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